A5021641803- Acute Myeloid Leukemia Research
- Hemophilia Treatment and Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Drug Transport and Resistance Mechanisms
- Multiple Myeloma Research and Treatments
- Neutropenia and Cancer Infections
- Platelet Disorders and Treatments
- Pharmaceutical studies and practices
- Hemoglobinopathies and Related Disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Histone Deacetylase Inhibitors Research
- Blood Coagulation and Thrombosis Mechanisms
- Renal Transplantation Outcomes and Treatments
- Hematopoietic Stem Cell Transplantation
- Pharmacological Effects and Toxicity Studies
- Safe Handling of Antineoplastic Drugs
- Pharmaceutical Practices and Patient Outcomes
- Lysosomal Storage Disorders Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Hemostasis and retained surgical items
- Chemotherapy-induced cardiotoxicity and mitigation
- Childhood Cancer Survivors' Quality of Life
Instituto de Investigación Sanitaria La Fe
2012-2025
Hospital Universitari i Politècnic La Fe
2016-2025
Agencia Española de Medicamentos y Productos Sanitarios
2021
Universitat de València
2020
Instituto Politécnico Nacional
2015
Secondary acute myeloid leukemia (sAML) comprises a heterogeneous group of patients and is associated with poor overall survival (OS). We analyze the characteristics, treatment patterns, outcomes adult sAML in Programa Español de Tratamientos en Hematología (PETHEMA) registry. Overall, 6211 (72.9%) were novo 2310 (27.1%) had sAML, divided into myelodysplastic syndrome AML (MDS-AML, 44%), MDS/myeloproliferative (MDS/MPN-AML, 10%), MPN-AML (11%), therapy-related (t-AML, 25%), antecedent...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces higher morbidity and mortality in hematological malignancies, but evidence myeloid leukemia (AML) is scarce. A multicenter observational study was conducted to determine the clinical outcomes assess impact of therapeutic approaches adult AML patients with SARS-CoV-2 first wave (March–May 2020). Overall, 108 were included: 51.9% active 70.4% under schedules for AML. Signs symptoms present 96.3% 82.4% received...
To analyse the differences in pharmacokinetic and clinical parameters (bleeding rates joint health) before after switching from standard half-life factor VIII (FVIII) to extended pegylated FVIII patients with severe/moderate haemophilia A on prophylaxis, 1 year switch real-life. This is a single-centre, comparative, observational, sequential, retrospective, multidisciplinary study. Population models WAPPS-Hemo® application were used calculate individualise prophylaxis. The annual rate of...
Von Willebrand Disease (vWD) is the most common congenital bleeding disorder, with an estimated prevalence in Spain of 0.01%. The aim was to assess cost-utility Haemate-P compared present alternatives treatment vWD Spain. A Markov model developed Microsoft Excel estimate cost-effectiveness various treatments for over a lifetime horizon. Transition probabilities among health states were based on age and number events. Treatment strategies included Haemate-P, Fanhdi, Wilate long-term...
Aim: In order to identify genetic variants associated with taxanes toxicity, a panel 47 SNPs in 20 genes involved taxane pathways was designed. Patients & methods: Genomic DNA of 113 breast cancer patients analyzed (70 taking docetaxel, 43 paclitaxel). Results: Two docetaxel toxicity were identified: CYP3A4*1B infusion-related reactions; and ERCC1 Gln504Lys mucositis (p ≤ 0.01). Regarding paclitaxel toxicity: CYP2C8 HapC rs1934951 anemia; neuropathy Conclusion: Genes repair mechanisms...
Abstract Objective Strength training is recommended for people with hemophilia; however, published data are anecdotal and have methodological limitations. The purpose of this study was to evaluate the safety effectiveness progressive moderate-to-vigorous intensity elastic resistance on physical function pain in patient population. Methods A randomized controlled trial conducted a university laboratory setting where 20 patients (17 severe, 1 moderate, 2 mild hemophilia) aged 21 53 years...
Anthracycline uptake could be affected by efflux pumps of the ABC family. The influence 7 SNPs genes was evaluated in 225 adult de novo acute myeloid leukemia (AML) patients. After multivariate logistic regression there were no significant differences complete remission, though induction death associated to ABCB1 triple variant haplotype (p = .020). related higher nephrotoxicity .016), as well this and allele rs1128503, rs2032582 hepatotoxicity .001; p .049; < .001). Furthermore, ABCC1...
Identifying polymorphisms in the dihydropyrimidine dehydrogenase (DPYD) gene is gaining importance to be able predict fluoropyrimidine-associated toxicity. The aim of this project was describe frequency DPYD variants DPYD*2A (rs3918290); c.1679T>G (rs55886062); c.2846A>T (rs67376798) and c.1129-5923C>G (rs75017182; HapB3) Spanish oncological patients.Cross-sectional multicentric study (PhotoDPYD study) conducted hospitals located Spain designed register most relevant genetic patients. All...
Lung transplant patients present important variability in immunosuppressant blood concentrations during the first months after transplantation. Pharmacogenetics could explain part of this interindividual variability. We evaluated SNPs genes that have previously shown correlations other kinds solid organ transplantation, namely ABCB1 and CYP3A5 with tacrolimus (Tac) ABCC2, UGT1A9 SLCO1B1 mycophenolic acid (MPA), six lung transplantation (51 patients). The genotype was correlated to trough...
<h3>Objectives</h3> To analyse the effectiveness and safety of baricitinib for severe COVID-19 in cytokine storm syndrome based on its potential role as an anti-inflammatory immunomodulator inhibitor viral endocytosis. <h3>Methods</h3> This was observational retrospective study hospitalised patients treated with COVID-19. Outcomes were clinical improvement ordinal scale 1–8 day 1 compared 14 (where 8=death 1=not no limitations activities), overall survival, time to recovery since treatment...
The incidence of cardiac morbimortality in acute myeloid leukemia (AML) is not well known. We aim to estimate the cumulative (CI) events AML patients and identify risk factors for their occurrence. Among 571 newly diagnosed patients, 26 (4.6%) developed fatal events, among 525 treated 19 (3.6%) experienced (CI: 2% at 6 months; 6.7% 9 years). Prior heart disease was associated with development (hazard ratio (HR) = 6.9). CI non-fatal 43.7% months 56.9% years. Age ≥ 65 (HR 2.2), relevant...